Bioventix PLC
LSE:BVXP
Bioventix PLC
LSE:BVXP
Price:
4 325 GBX
Market Closed
Updated:
May 3, 2024
Bioventix PLC
Operating Income
|
Bioventix PLC
Operating Income Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bioventix PLC
LSE:BVXP
|
Operating Income
£10.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$189.4m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is Bioventix PLC's Operating Income?
Operating Income
10.8m
GBP
10.8m
GBP
Based on the financial report for Dec 31, 2023, Bioventix PLC's Operating Income amounts to 10.8m GBP.
What is Bioventix PLC's Operating Income growth rate?
Operating Income CAGR 10Y
18%
18%
Over the last year, the Operating Income growth was 6%. The average annual Operating Income growth rates for Bioventix PLC have been 12% over the past three years , 10% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
